Kemp Dolliver

Stock Analyst at Brookline Capital

(0.64)
# 4,122
Out of 5,147 analysts
19
Total ratings
38.46%
Success rate
-13.96%
Average return

Stocks Rated by Kemp Dolliver

Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $4.10
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.14
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $5.47
Upside: +210.79%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.99
Upside: +260.72%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.82
Upside: +27.66%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.70
Upside: +2,017.65%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.42
Upside: +7,363.75%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $74.91
Upside: +33.49%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.20
Upside: +2,490.91%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.98
Upside: +738.93%
Initiates: Buy
Price Target: $19
Current: $7.58
Upside: +147.36%
Assumes: Buy
Price Target: $8
Current: $0.75
Upside: +966.67%
Initiates: Buy
Price Target: $5.65
Current: $0.58
Upside: +877.85%